XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference36 articles.
1. Cancer statistics, 2010;Jemal;CA Cancer J Clin,2010
2. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;Ozols;J Clin Oncol,2003
3. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J Natl Cancer Inst,2003
4. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study;Hoskins;Gynecol Oncol,1992
5. Survival among U.S. women with invasive epithelial ovarian cancer;McGuire;Gynecol Oncol,2002
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapeutic drug monitoring of selected anticancer drugs;Therapeutic Drug Monitoring;2024
2. Association between XRCC1 Arg399Gln polymorphism with prognosis of head and neck squamous cell carcinomas: A meta-analysis;Heliyon;2023-10
3. The Research Progress of XRCC1 in Tumor;Advances in Clinical Medicine;2023
4. Effect and mechanism of miR-217 on drug resistance, invasion and metastasis of ovarian cancer cells through a regulatory axis of CUL4B gene silencing/inhibited Wnt/β-catenin signaling pathway activation;EUR REV MED PHARMACO;2021
5. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas;Current Drug Targets;2020-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3